Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy versus chemotherapy plus pembrolizumab in biomarker-selected advanced non-small cell lung cancer
NL-OMON56597Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Carboplatin + pemetrexed + pembrolizumab with Carboplatin + pemetrexed (2 arms). Primary endpoint: Objective response rate. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56597.